268 related articles for article (PubMed ID: 16473372)
1. Notch-1 immunoexpression is increased in Alzheimer's and Pick's disease.
Nagarsheth MH; Viehman A; Lippa SM; Lippa CF
J Neurol Sci; 2006 May; 244(1-2):111-6. PubMed ID: 16473372
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
3. Expression of transcription factors c-Fos, c-Jun, CREB-1 and ATF-2, and caspase-3 in relation with abnormal tau deposits in Pick's disease.
Nieto-Bodelón M; Santpere G; Torrejón-Escribano B; Puig B; Ferrer I
Acta Neuropathol; 2006 Apr; 111(4):341-50. PubMed ID: 16496165
[TBL] [Abstract][Full Text] [Related]
4. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
[TBL] [Abstract][Full Text] [Related]
5. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
6. Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice.
Huesa G; Baltrons MA; Gómez-Ramos P; Morán A; García A; Hidalgo J; Francés S; Santpere G; Ferrer I; Galea E
J Alzheimers Dis; 2010; 19(1):37-56. PubMed ID: 20061625
[TBL] [Abstract][Full Text] [Related]
7. Pick bodies in a family with presenilin-1 Alzheimer's disease.
Halliday GM; Song YJ; Lepar G; Brooks WS; Kwok JB; Kersaitis C; Gregory G; Shepherd CE; Rahimi F; Schofield PR; Kril JJ
Ann Neurol; 2005 Jan; 57(1):139-43. PubMed ID: 15622541
[TBL] [Abstract][Full Text] [Related]
8. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies.
Santpere G; Nieto M; Puig B; Ferrer I
Neurosci Lett; 2006 Apr 10-17; 397(1-2):30-4. PubMed ID: 16378688
[TBL] [Abstract][Full Text] [Related]
9. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders.
Joachim CL; Morris JH; Kosik KS; Selkoe DJ
Ann Neurol; 1987 Oct; 22(4):514-20. PubMed ID: 2963585
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation and cleavage of tau in non-AD tauopathies.
Guillozet-Bongaarts AL; Glajch KE; Libson EG; Cahill ME; Bigio E; Berry RW; Binder LI
Acta Neuropathol; 2007 May; 113(5):513-20. PubMed ID: 17357802
[TBL] [Abstract][Full Text] [Related]
11. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
Wang YJ; Chen GH; Hu XY; Lu YP; Zhou JN; Liu RY
Brain Res; 2005 Jan; 1031(1):101-8. PubMed ID: 15621017
[TBL] [Abstract][Full Text] [Related]
12. Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology.
Newman J; Rissman RA; Sarsoza F; Kim RC; Dick M; Bennett DA; Cotman CW; Rohn TT; Head E
Acta Neuropathol; 2005 Aug; 110(2):135-44. PubMed ID: 15986225
[TBL] [Abstract][Full Text] [Related]
13. The evolution and pathology of frontotemporal dementia.
Kertesz A; McMonagle P; Blair M; Davidson W; Munoz DG
Brain; 2005 Sep; 128(Pt 9):1996-2005. PubMed ID: 16033782
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
15. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease.
Ferrer I; Freixas M; Blanco R; Carmona M; Puig B
Neuropathol Appl Neurobiol; 2004 Aug; 30(4):329-37. PubMed ID: 15305978
[TBL] [Abstract][Full Text] [Related]
16. Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies.
Lagalwar S; Berry RW; Binder LI
Acta Neuropathol; 2007 Jan; 113(1):63-73. PubMed ID: 17089132
[TBL] [Abstract][Full Text] [Related]
17. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease.
Attems J; Preusser M; Grosinger-Quass M; Wagner L; Lintner F; Jellinger K
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):23-32. PubMed ID: 17961140
[TBL] [Abstract][Full Text] [Related]
18. Aberrant localization of importin alpha1 in hippocampal neurons in Alzheimer disease.
Lee HG; Ueda M; Miyamoto Y; Yoneda Y; Perry G; Smith MA; Zhu X
Brain Res; 2006 Dec; 1124(1):1-4. PubMed ID: 17070506
[TBL] [Abstract][Full Text] [Related]
19. Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease.
Takeda T; Uchihara T; Arai N; Mizutani T; Iwata M
Acta Neuropathol; 2009 Jan; 117(1):35-44. PubMed ID: 19002475
[TBL] [Abstract][Full Text] [Related]
20. Silver staining profiles distinguish Pick bodies from neurofibrillary tangles of Alzheimer type: comparison between Gallyas and Campbell-Switzer methods.
Uchihara T; Tsuchiya K; Nakamura A; Akiyama H
Acta Neuropathol; 2005 May; 109(5):483-9. PubMed ID: 15759128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
